Skip to main content
Premium Trial:

Request an Annual Quote

FoxHollow Licenses Rosetta Resolver for Atherosclerosis Project with Merck

NEW YORK, March 13 (GenomeWeb News) - FoxHollow Technologies has licensed the Rosetta Resolver system for research on cardiovascular disease, Rosetta Biosoftware said today.

 

FoxHollow will use the application to correlate genetic profiles of human atherosclerotic plaque samples to develop therapies, according to a statement. The data for analysis comes from a September 2005 pharmacogenomic collaboration between FoxHollow and Merck.

 

Financial details were not released.

 

Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.